Literature DB >> 7883823

Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism.

S J Silverberg1, F Gartenberg, T P Jacobs, E Shane, E Siris, R B Staron, J P Bilezikian.   

Abstract

A large number of patients with primary hyperparathyroidism today do not undergo parathyroidectomy. In this prospective study, we evaluated the effect of untreated disease on biochemical and bone densitometric indices. In 66 patients, seven annual measurements showed no change in serum calcium, phosphorus, PTH, vitamin D, or alkaline phosphatase; in urinary calcium, hydroxyproline or hydroxypyridinium cross-link excretion; or lumbar spine, femoral neck, and radial bone mineral density. The subset of postmenopausal women also showed no change in biochemical indices or bone density at any of the three sites. Twenty-four patients met guidelines for surgery as established by the NIH Consensus Conference, 1990. They differed from those who did not meet these guidelines only by being younger (50 +/- 3 vs. 62 +/- 2 yr; P = 0.0005) and by having higher urinary calcium excretion [7.7 +/- 0.9 vs. 5.4 +/- 0.3 mmol/L (310 +/- 37 vs. 215 +/- 14 mg/g creatinine); P < 0.01]. No longitudinal changes in biochemical profile or bone mineral density at any site were noted in this subgroup. Conservative management of patients with mild primary hyperparathyroidism does not lead to progression of disease, as reflected by biochemical indices. Bone density is maintained over 6 yr of observation at sites reflecting both cortical (radius) and cancellous (lumbar spine) bone.

Entities:  

Mesh:

Year:  1995        PMID: 7883823     DOI: 10.1210/jcem.80.3.7883823

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  Parathyroidectomy for asymptomatic primary hyperparathyroidism (PHPT): is it worth the risk?

Authors:  D S Rao
Journal:  J Endocrinol Invest       Date:  2001-02       Impact factor: 4.256

2.  Minimum sample size requirements for bone density precision assessment produce inconsistency in clinical monitoring.

Authors:  W D Leslie; A Moayyeri
Journal:  Osteoporos Int       Date:  2006-08-10       Impact factor: 4.507

3.  Correlations of dual-energy X-ray absorptiometry, quantitative computed tomography, and single photon absorptiometry with spinal and non-spinal fractures.

Authors:  F W Lafferty; D Y Rowland
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

4.  Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report.

Authors:  T Diamond; A T Ng; S Levy; C Magarey; R Smart
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

5.  Multifactorial risk profile for bone fractures in primary hyperparathyroidism.

Authors:  Erik Nordenström; Johan Westerdahl; Birger Lindergård; Pia Lindblom; Anders Bergenfelz
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

Review 6.  Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.

Authors:  Donovan Tay; Serge Cremers; John P Bilezikian
Journal:  Br J Clin Pharmacol       Date:  2017-12-06       Impact factor: 4.335

Review 7.  Epidemiology and pathophysiology of osteoporosis in men.

Authors:  Robert A Adler
Journal:  Curr Osteoporos Rep       Date:  2006-09       Impact factor: 5.096

Review 8.  What symptom improvement can be expected after operation for primary hyperparathyroidism?

Authors:  Nadine R Caron; Janice L Pasieka
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

Review 9.  Bone turnover markers in primary hyperparathyroidism.

Authors:  Aline G Costa; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

10.  Predictors of bone mineral density improvement in patients undergoing parathyroidectomy for primary hyperparathyroidism.

Authors:  Jyotirmay Sharma; Dina S Itum; Lewis Moss; C Li; Christine Chun-Li; Collin Weber
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.